172 related articles for article (PubMed ID: 34186055)
1. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
[TBL] [Abstract][Full Text] [Related]
2. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
3. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.
Cello G; Patel RV; McMahon JT; Santagata S; Bi WL
Acta Neuropathol Commun; 2023 Jul; 11(1):122. PubMed ID: 37491289
[TBL] [Abstract][Full Text] [Related]
4. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
Behling F; Fodi C; Gepfner-Tuma I; Kaltenbach K; Renovanz M; Paulsen F; Skardelly M; Honegger J; Tatagiba M; ; Schittenhelm J; Tabatabai G
Neuro Oncol; 2021 Aug; 23(8):1273-1281. PubMed ID: 33367841
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
Samal S; Patnaik A; Sahu F; Purkait S
Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
[TBL] [Abstract][Full Text] [Related]
6. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
Hua L; Ren L; Wu Q; Deng J; Chen J; Cheng H; Wang D; Chen H; Xie Q; Wakimoto H; Gong Y
J Neurooncol; 2023 Jan; 161(2):267-275. PubMed ID: 36329368
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Relevance of H3K27 Trimethylation Loss in Meningioma: A Systematic Review of Recurrence and Overall Survival with Meta-Analysis.
Lu VM; Luther EM; Eichberg DG; Morell AA; Shah AH; Komotar RJ; Ivan ME
World Neurosurg; 2022 Jul; 163():87-95.e1. PubMed ID: 35439620
[TBL] [Abstract][Full Text] [Related]
8. Loss of H3K27me3 in WHO grade 3 meningioma.
Maier AD; Brøchner CB; Mirian C; Haslund-Vinding J; Bartek J; Ekström TJ; Poulsen FR; Scheie D; Mathiesen T
Brain Tumor Pathol; 2022 Oct; 39(4):200-209. PubMed ID: 35678886
[TBL] [Abstract][Full Text] [Related]
9. Loss of H3K27me3 in meningiomas.
Nassiri F; Wang JZ; Singh O; Karimi S; Dalcourt T; Ijad N; Pirouzmand N; Ng HK; Saladino A; Pollo B; Dimeco F; Yip S; Gao A; Aldape KD; Zadeh G;
Neuro Oncol; 2021 Aug; 23(8):1282-1291. PubMed ID: 33970242
[TBL] [Abstract][Full Text] [Related]
10. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.
Gauchotte G; Peyre M; Pouget C; Cazals-Hatem D; Polivka M; Rech F; Varlet P; Loiseau H; Lacomme S; Mokhtari K; Kalamarides M; Bielle F
J Neuropathol Exp Neurol; 2020 Jul; 79(7):754-762. PubMed ID: 32447376
[TBL] [Abstract][Full Text] [Related]
12. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.
Ehret F; Perez E; Teichmann D; Meier S; Geiler C; Zeus C; Franke H; Roohani S; Wasilewski D; Onken J; Vajkoczy P; Schweizer L; Kaul D; Capper D
Acta Neuropathol Commun; 2024 May; 12(1):74. PubMed ID: 38720399
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
[TBL] [Abstract][Full Text] [Related]
17. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
18. A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.
Chen WC; Vasudevan HN; Choudhury A; Pekmezci M; Lucas CG; Phillips J; Magill ST; Susko MS; Braunstein SE; Oberheim Bush NA; Boreta L; Nakamura JL; Villanueva-Meyer JE; Sneed PK; Perry A; McDermott MW; Solomon DA; Theodosopoulos PV; Raleigh DR
Neurosurgery; 2020 Dec; 88(1):202-210. PubMed ID: 32860417
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome.
Bertero L; Dalla Dea G; Osella-Abate S; Botta C; Castellano I; Morra I; Pollo B; Calatozzolo C; Patriarca S; Mantovani C; Rudà R; Tardivo V; Zenga F; Garbossa D; Papotti M; Soffietti R; Ricardi U; Cassoni P
J Neuropathol Exp Neurol; 2019 Mar; 78(3):248-256. PubMed ID: 30689922
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
